May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?

Nutr Metab Cardiovasc Dis. 2020 Jun 25;30(7):1068-1069. doi: 10.1016/j.numecd.2020.05.003. Epub 2020 May 13.
No abstract available

Publication types

  • Letter
  • Review

MeSH terms

  • Adult
  • Age Factors
  • COVID-19
  • Cause of Death
  • China
  • Comorbidity
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / prevention & control*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipoproteinemia Type II / diagnosis
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type II / epidemiology*
  • Incidence
  • Male
  • Middle Aged
  • Pandemics / prevention & control*
  • Pandemics / statistics & numerical data
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / prevention & control*
  • Prognosis
  • Proprotein Convertase 9 / drug effects*
  • Proprotein Convertase 9 / genetics
  • Proprotein Convertase 9 / therapeutic use
  • Risk Assessment
  • Sex Factors
  • Survival Analysis
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9